scholarly journals Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case

Viruses ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2143
Author(s):  
Fabiana Gil Melgaço ◽  
Tamiris Azamor ◽  
Livia Melo Villar ◽  
Ana Paula Dinis Ano Bom ◽  
Juliana Gil Melgaço
Keyword(s):  
Crohn’S Disease ◽  
T Cell ◽  
Crohn's Disease ◽  
T Cell Activation ◽  
Cell Activation ◽  
Disease Patient ◽  
Antibody Detection ◽  
Cell Responses ◽  
Cell Immunity ◽  
The Impact

Vaccines to prevent the impact of SARS-CoV-2 are now available, including for patients with autoimmune diseases. However, there is no information about how inflammatory bowel disease (IBD) treatment could impact the cellular and humoral immune responses. This study evaluated SARS-CoV-2-specific humoral and cellular responses after vaccination with a two-dose schedule in a Crohn’s disease patient treated with Infliximab (10 mg/kg); we included comparisons with a monozygotic twin. The results showed that the Crohn’s disease’s twin (twin 2) had no antibody detection and reduced activation of CD4+ T cell responses, unlike the twin without the autoimmune disease (twin 1). Twin 2 developed antigen-specific central memory CD8+ T-cells and IFNγ production after the second dose of COVID-19 vaccination, similar to twin 1. These findings elucidated the role of T-cell immunity after COVID-19 immunization on IBD patients despite the lack of antibody production. Finally, our observation supports the consensus recommendation for IBD patients to receive COVID-19 vaccines.

Inhibitor of interleukin-1? and interleukin-1?-induced T-cell activation in serum of patients with active Crohn's disease

1991 ◽  
Vol 36 (6) ◽  
pp. 737-742 ◽  
Author(s):  
J�rn Brynskov ◽  
Morten Bagge Hansen ◽  
Claus Reimert ◽  
Klaus Bendtzen
Keyword(s):  
Crohn’S Disease ◽  
T Cell ◽  
Crohn's Disease ◽  
T Cell Activation ◽  
Cell Activation ◽  
Interleukin 1

T-cell activation in Crohn's disease

1990 ◽  
Vol 98 (3) ◽  
pp. 639-646 ◽  
Author(s):  
Ch. Mueller ◽  
P. Knoflach ◽  
C.C. Zielinski
Keyword(s):  
Crohn’S Disease ◽  
T Cell ◽  
Crohn's Disease ◽  
T Cell Activation ◽  
Cell Activation

scholarly journals Integrated Bioinformatics Analysis Identifies ELAVL1 and APP as Candidate Crucial Genes for Crohn’s Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-20
Author(s):  
Heli Li ◽  
Qianru Li ◽  
Shiran Sun ◽  
Ping Lei ◽  
Xiong Cai ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
T Cell ◽  
Crohn's Disease ◽  
Signaling Pathway ◽  
T Cell Activation ◽  
Peripheral Blood ◽  
Cell Activation ◽  
Mapk Signaling ◽  
Gene Set Enrichment Analysis ◽  
Infliximab Treatment

Immune imbalance and barrier destruction of intestinal mucosa are the central pathogenic factors of Crohn’s disease (CD). In this study, three independent microarray studies of CD were integrated and 9912 differentially expressed genes (DEGs) were analysed by NetworkAnalyst to screen candidate crucial genes. NetworkAnalyst identified ELAV-like RNA binding protein 1 (ELAVL1) as the most crucial upregulated gene and amyloid-β precursor protein (APP) as the most crucial downregulated gene in peripheral blood of CD patients. By computing significance with hypergeometric test based on the KEGG pathway database, upregulated DEGs highlight the pathways of T cell receptor signaling and the differentiation of T helpers. Downregulated DEGs were found enriched in pathways in multiple cancers, MAPK signaling, Rap1 signaling, and PI3K-AKT signaling. Further taking all DEGs together, Gene Set Enrichment Analysis (GSEA) brought out the NOD-like receptor (NLR) signaling pathway which could be regulated by ELAVL1. xCell found decreased naïve and differentiated T cell proportions in the peripheral blood of CD patients suggesting T cell migration to the intestinal tissue and/or exhaustion. Further, ELAVL1 expression correlating with multiple T cell proportions suggests that ELAVL1 may regulate T cell activation. These findings illustrated that ELAVL1 and APP were candidate crucial genes in the peripheral blood of CD patients. ELAVL1 possibly acts as a key regulator of T cell activation via the NLR signaling pathway. APP might be a downstream effector of infliximab treatment connecting with MAPK signaling.

scholarly journals SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients

2021 ◽  
Vol 6 (58) ◽  
pp. eabf7550
Author(s):  
Sunil Kumar Saini ◽  
Ditte Stampe Hersby ◽  
Tripti Tamhane ◽  
Helle Rus Povlsen ◽  
Susana Patricia Amaya Hernandez ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
T Cell Activation ◽  
Cell Activation ◽  
T Cell Responses ◽  
T Cell Immunity ◽  
Cell Recognition ◽  
T Cell Recognition ◽  
Cell Responses ◽  
Cell Immunity

T cells are important for effective viral clearance, elimination of virus-infected cells and long-term disease protection. To examine the full-spectrum of CD8+ T cell immunity in COVID-19, we experimentally evaluated 3141 major histocompatibility (MHC) class I-binding peptides covering the complete SARS-CoV-2 genome. Using DNA-barcoded peptide-MHC complex (pMHC) multimers combined with a T cell phenotype panel, we report a comprehensive list of 122 immunogenic and a subset of immunodominant SARS-CoV-2 T cell epitopes. Substantial CD8+ T cell recognition was observed in COVID-19 patients, with up to 27% of all CD8+ lymphocytes interacting with SARS-CoV-2-derived epitopes. Most immunogenic regions were derived from open reading frame (ORF) 1 and ORF3, with ORF1 containing most of the immunodominant epitopes. CD8+ T cell recognition of lower affinity was also observed in healthy donors toward SARS-CoV-2-derived epitopes. This pre-existing T cell recognition signature was partially overlapping with the epitope landscape observed in COVID-19 patients and may drive the further expansion of T cell responses to SARS-CoV-2 infection. Importantly the phenotype of the SARS-CoV-2-specific CD8+ T cells, revealed a strong T cell activation in COVID-19 patients, while minimal T cell activation was seen in healthy individuals. We found that patients with severe disease displayed significantly larger SARS-CoV-2-specific T cell populations compared to patients with mild diseases and these T cells displayed a robust activation profile. These results further our understanding of T cell immunity to SARS-CoV-2 infection and hypothesize that strong antigen-specific T cell responses are associated with different disease outcomes.

T-cell activation Rho GTPase–activating protein expression varies with inflammation location and severity in Crohn's disease

2014 ◽  
Vol 190 (2) ◽  
pp. 457-464 ◽  
Author(s):  
Tara M. Connelly ◽  
Arthur S. Berg ◽  
Leonard R. Harris ◽  
John P. Hegarty ◽  
Francesca M. Ruggiero ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
T Cell ◽  
Crohn's Disease ◽  
Protein Expression ◽  
T Cell Activation ◽  
Cell Activation ◽  
Rho Gtpase ◽  
Gtpase Activating Protein
Sign in / Sign up

Export Citation Format

Share Document